2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Proopiomelanocortin Deficiency: new trials by email Literature Review of Proopiomelanocortin Deficiency trials Research Report on Proopiomelanocortin Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity Setmelanotide - Bardet-Biedl Syndrome, POMC Deficiency Obesity | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 12 | 2022-03-08 | 2024-11-27 |
| Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg - Bardet-Biedl Syndrome, POMC Deficiency | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 19 | 2021-12-21 | 2024-11-26 |
Bardet-Biedl Syndrome (2) · Hyperphagia (1) · Obesity (1) · Pediatric Obesity (1)
Abnormalities, Multiple (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Ciliopathies (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Hypothalamic Diseases (2) · Nervous System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Retinitis Pigmentosa (2) · Signs and Symptoms (2) · Body Weight (1)
setmelanotide (2)
Rhythm Pharmaceuticals, Inc. (2)
United Kingdom (2) · United States (2) · Australia (1) · Canada (1) · Germany (1) · Netherlands (1) · Puerto Rico (1) · Spain (1)
David Meeker, MD (2)